CCM
IMMX icon

Context Capital Management’s Immix Biopharma IMMX Stock Holding History

Context Capital Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,532
Closed -$41K – 697
2021
Q4 		$41K Buy
+11,532
New +$39.5K ﹤0.01% 484

Other funds holding IMMX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ICG
InterOcean Capital Group Nashville, Tennessee $4.19B AUM 26.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Context Capital Management's IMMX Position: Q1 2022 in Review

Context Capital Management sold out of Immix Biopharma (IMMX) in Q1 2022, closing a stake of 11,532 shares — an estimated $41K sold.

Context Capital Management first reported a position in IMMX in Q4 2021 and held it in 1 quarter. The position peaked at $41K in Q4 2021. 8 funds tracked by Wall St. Rank hold IMMX as of Q1 2022.

  • Context Capital Management reported no remaining Immix Biopharma position as of Q1 2022 after selling out during the quarter.
  • Context Capital Management sold 11,532 Immix Biopharma shares in Q1 2022, an estimated $41K.
  • Context Capital Management first reported a position in Immix Biopharma in Q4 2021 and held it in 1 quarter.
  • Context Capital Management's Immix Biopharma position peaked at $41K in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2022.

Based on Context Capital Management's 13F filing for Q1 2022, filed 9 May 2022.